Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Ohio State University Comprehensive Cancer Center
Trishula Therapeutics, Inc.
Bank of Cyprus Oncology Centre
Wake Forest University Health Sciences
Thomas Jefferson University
Inspirna, Inc.
Spanish Lung Cancer Group
Intensity Therapeutics, Inc.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
National Cancer Institute (NCI)
Celldex Therapeutics
University of California, San Francisco
Mural Oncology, Inc
Corvus Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Yale University
Hospital Israelita Albert Einstein
Aetion, Inc.
Cantargia AB
Viralytics
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
Syndax Pharmaceuticals
Incyte Corporation
BioNTech SE
Centre hospitalier de l'Université de Montréal (CHUM)
Gary Onik MD